Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX) in the last three months. In the table below ...

Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.

Pinnacle Associates Ltd. reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 44.4% in the ...

Phil Nadeau, an analyst from TD Cowen, maintained the Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price target remains the same with $525.00. Phil Nadeau’s ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.

Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter. The biotechnology company on Monday posted a quarterly net profit of $1.05 ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

(Reuters) - Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects ...